REFERENCES:

1. World Health Organization, Health Topics, Mental disorders (2011), Available http://www.who.int/topics/mental_disorders/en/.

2. World Health Organization, Mental health: strengthening our response (2011), Available http://www.who.int/mediacentre/factsheets/fs220/en/

3. Catherine Griffin (2013). Five Very Different and Major Psych Disorders Have Shared Genetics". Science World Report. Available http://www.scienceworldreport.com/articles/5266/20130228/five-very-different-major-psych-disorders-shared-genetics.htm

4. American Psychiatric Association, DSM (2011), Available http://www.psych.org/practice/dsm

5. National Institutes of Health, National Institute of Mental Health (2013), Statistics: Any Disorder Among Adults. Available http://www.nimh.nih.gov/statistics/1ANYDIS_ADULT.shtml

6. Alyssia Klein (Mar. 25, 2011), Schizophrenia epidemiology: Data monitor Healthcare

7. Frances R Frankenburg. Schizophrenia (2013), Available http://emedicine.medscape.com/article/288259-overview#aw2aab6b2b3

8. Selten JP, Cantor-Graae E, Kahn RS (2007), Migration and schizophrenia, Curr Opin Psychiatry, 20(2), 111-5.

9. Bourque F, van der Ven E, Malla A (2011), A meta-analysis of the risk for psychotic disorders among first- and second-generation immigrants, Psychol Med. May, 41(5), 897-910.

10. Kirkbride J, Coid JW, Morgan C, *et al.* (2010), Translating the epidemiology of psychosis into public mental health: evidence, challenges and future prospects, J Public Ment Health, 9(2), 4-14.

11. Kety SS, Wender PH, Jacobsen B, *et al.* (1994), Mental illness in the biological and adoptive relatives of schizophrenic adoptees. Replication of the Copenhagen Study in the rest of Denmark. Arch Gen Psychiatry, 51(6), 442-55.

12. Girard SL, Gauthier J, Noreau A, *et al.* (2011), Increased exonic de novo mutation rate in individuals with schizophrenia. Nat Genet., 43(9), 860-3.

13. Clarke MC, Tanskanen A, Huttunen M, Whittaker JC, Cannon M. (2009), Evidence for an interaction between familial liability and prenatal exposure to infection in the causation of schizophrenia,. Am. J. Psychiatry, 166(9), 1025-30.

14. Daniel Chancellor (2012), Schizophrenia forecast, Data monitor Healthcare.

15. Wikinvest, Wiki Analysis (2008), Available http://www.wikinvest.com/wiki/Central_Nervous_System_Drug_Market

16. Brahmankar DM, Jaiswal SB (1999), Biopharmaceutics and pharmacokinetics, Treatise A.,Vallabh Prakashan, Delhi, 335-57.

17. Gibaldi M (1984), Biopharmaceutics and clinical pharmacokinetics, 3rd edition, Lea and Febiger, Philadelphia, 576-78.

18. Mihajlovic T, Kachrimanis K, Graovac A, Djuric Z, Ibric S (2012), Improvement of Aripiprazole solubility by complexation with (2-hydroxy)propyl-β-cyclodextrin using spray drying technique, AAPS Pharmaceutical Science and Technology, 13(2), 623-31.

19. Xu Y, Liu X, Lian R, Zheng S, Yin Z, Lu Y, Wu W. (2012), Enhanced dissolution and oral bioavailability of aripiprazole nanosuspensions prepared by nanoprecipitation/ homogenization based on acid-base neutralization, International Journal of Pharmaceutics, 438 (1-2); 287-295.

20. Dreyer Katja, Loeffler Uwe, Glaenzer Klaus (2010), Amorphous aripiprazole and process for the preparation thereof, US7799790B2.

21. Hemanth Bhaurao Banbale, Prasad Gajanan Patil, Shailesh Suresh Bhamare, Deo Kishor Dattatray, Meenakshisunderam Sivakumaran (2012), Aripiprazole Compositions, IN3074/CHE/2009.

22. Uslu Abdullah (2008), Pharmaceutical compositions comprising aripiprazole, WO2008020820

23. Ettema Gerrit J. B., Westheim; Raymond J. H., Kalmoua; Faysal (2010),. Process of making crystalline Type II aripiprazole, US7655798B2.

24. Sheth, Rakesh (2010), Pharmaceutical composition of aripiprazole, WO 2010/079506.

25. Choy, Jin Ho; OH, Yeon Ji; PARK, Myung Chul; CHANG, Hee Chul (2011), Aripiprazole-bentonite-AEA hybrid pharmaceuticals, WO2011031100A2.

26. Jingyi Wang, Changjun Li, Jingcan Wang, Qingmin Yang, Ying Li, Minghui Zhang (2011), Oral disintegrating tablets of microcrystallites of aripiprazole composition and preparation method thereof, CN102218040A.

27. Nguyen Thanh-Tam (2012), Oral lyophilized compositions, US20120245156A1.

28. Liu; Fang-yu, Shen; Zhi-qun (2012), Stabilized atypical antipsychotic formulation, US8173637B1.

29. Prasade R.R. *et al.* (2009), Orally disintegrating compositions of antipsychotic agents, IN2007CH02681A.

30. Wilding, Ian; Pendleton, Russell (2007), Controlled-release pharmaceutical compositions containing Aripiprazole, WO 2008038003.

31. Jie Deng *et al.* (2010), Solid oral drug composite containing aripiprazole microcrystalline, CN101791287B.

32. Hrakovsky Julia *et al.* (2007), Dry formulations of aripiprazole, US20070154545A1.

33. Hrakovsky Julia *et al.* (2007), Wet granulation formulations of aripiprazole, US20070154544A1.

34. Lulla Amar *et al.* (2012), Pharmaceutical formulation, IN2010MU00527.

35. Liu, Fang-Yu; Shen, Zhi-Qun (2008), Stabilized atypical antipsychotic formulation, WO 2010011232.

36. Li, Z. M.; Zhang, W *et al.* (2012), Preparation of venlafaxine hydrochloride sustained-release capsules by extrusion-spheronization, Shipin Yu Yaopin, 14(11), 406-408.

37. Bagdiya, O.; Sav, A.K. *et al.* (2013), Formulation development of Venlafaxine hydrochloride extended release pellets by extrusion spheronization method; International Journal of Pharmacy, 3(1), 152-159.

38. Tripathi, J. K.; Sharma, D. K. *et al.* (2012), Effect of water uptake on particle size distribution of core pellets of Venlafaxine HCl prepared by extrusion and Spheronization technique; Novel Science International Journal of Pharmaceutical Science, 1(6), 389-394.

39. Zhang, H.; Guo, S. *et al.* (2012), Preparation of venlafaxine hydrochloride sustained-release capsules; Qilu Yaoshi, 31(5), 252-253.

40. Kumar, M. S.; Das, B. *et al.* (2012), Formulation and evaluation of multi-unit pellet system of Venlafaxine hydrochloride; Journal of Pharmaceutical and Biomedical Sciences ,1(18), 05.

41. Liu, Y.; Sun, Y. *et al.* (2012), Preparation and *in-vitro*/in vivo evaluation of sustained-release venlafaxine hydrochloride pellets, International Journal of Pharmaceutics, 426(1-2), 21-28.

42. Guan, T.; Wang, J. *et al.* (2011), Comparative study of the stability of venlafaxine hydrochloride sustained-release pellets prepared by double-polymer coatings and hot-melt subcoating combined with Eudragit NE30D outercoating. Pharmaceutical Development and Technology, 16(3), 269-277.

43. Bhushan, R. S.; Krishnaji, K. S. *et al.* (2010), Modified release pharmaceutical composition of venlafaxine hydrochloride, Indian Patent Application No. IN 2009/MUM/1277 A.

44. Tian, L.; Zhang; *et al.* (2008), Sustained-Release Pellets Prepared by Combination of Wax Matrixes and Double-Layer Coatings for Extremely Water-Soluble Drugs, Drug Development and Industrial Pharmacy, 34(6), 569-576.

45. Odidi, Isa; Odidi, Amina (2007), Drug delivery compositions, extruded spheroids comprising active pharmaceutical ingredient, extrusion-spheronization aid, superdisintegrant, glidant, lubricant, and oil, WO 2007112579 A1.

46. Ding, Qiang; Li, Cong-yan; Yan, Hong-bing (2007), Preparation of venlafaxine hydrochloride sustained release pellets and its release test *in-vitro*, Zhongguo Xiandai Yingyong Yaoxue, 24(6), 482-484.

47. Madat, Dhaval V.; Gohel, Mukesh C. (2011), Statistical optimization of venlafaxine hydrochloride controlled release pellets prepared employing the blend of ethyl cellulose and HPMC, Journal of Pharmacy Research, 4(3), 607-609.

48. Liu, Yang; *et al.* (2012), Preparation and *in-vitro*/in vivo evaluation of sustained-release venlafaxine hydrochloride pellets, International Journal of Pharmaceutics (Amsterdam, Netherlands), 426(1-2), 21-28.

49. Seetharaman, Sritharan; Nallaperumal, Narayanan (2012), Once daily Venlafaxine hydrochloride extended release tablets: comparison between matrix tablet and pellets, International Journal of Pharmaceutical Sciences Review and Research, 13(1), 149-153.

50. Akelesh, T.; Rakesh, S.; Ramya, R.; Venkatnarayanan, R. (2011) Formulation development and evaluation of venlafaxine hydrochloride sustained release pellets, Journal of Pharmacy Research, 4(10), 3287-3289.